Atrial Fibrillation
Conditions
Keywords
atrial fibrillation;left atrial function
Brief summary
A total of 120 patients with persistent atrial fibrillation (including continuous and long-standing persistent atrial fibrillation) and 60 patients with paroxysmal atrial fibrillation will receive radiofrequency ablation. Patients in each group will be randomly allocated into the statin treatment group and non-statin treatment group (allocation ratio, 1:1). Left atrial appendage flow velocity of all patients are measured by Transesophageal Echocardiography(TEE) 24 hours before the operation. Real-time ultrasound examinations of left atrial function are carried out for all patients before the operation and after the operation. Blood samples are extracted in all patients before the operation and after the operation. This study will clarify whether the application of statin drugs can improve postoperative left atrial function. This study will identify the time course and influence factors of left atrial recovery of atrial fibrillation after the operation to guide the time and the degree of anticoagulation and effectively prevent thromboembolic events. At the same time, biochemical indicators are detected to analyze which indicators are related to the postoperative recurrence of atrial fibrillation, the incidence of postoperative thrombosis and the recovery of postoperative left atrial function. Furthermore, this study will investigate whether the application of statin drugs can improve postoperative left atrial function by affecting these indicators.
Interventions
Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
DRUGnon-atorvastatin group
Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
Sponsors
xieruiqin
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
No minimum to 80 Years
Healthy volunteers
No
Inclusion criteria
* All persistent or permanent AF patients with refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication. * paroxysmal atrial fibrillation with refractory or intolerant to at least one Class 1 or Class 3 antiarrhythmic medication. * age is \<80 years
Exclusion criteria
* left ventricular dysfunction * LA \>50 mm * atrial thrombosis * valvular heart disease * hyperthyroidism * patients who underwent prosthetic heart valve replacement * patients with previous history of atrial fibrillation ablation * Hyperlipidemia * pregnant women * patients with existing liver and kidney disease * malignant tumors * hematological system diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Left atrial function of postoperative atrial fibrillation detected | 1-12 month |
Secondary
| Measure | Time frame |
|---|---|
| Plasma biomarkers of inflammation,myocardial injury and prothrombotic assessed | 1-3 month |
Countries
China
Outcome results
None listed